N-{(5S)-3-[4-(5,6-dihydro-2H,4H-2-methylpyrrolo[3,4-c]pyrazol-5-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl-methyl}acetamide | 474016-05-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡唑类
• 英文名称: N-{(5S)-3-[4-(5,6-dihydro-2H,4H-2-methylpyrrolo[3,4-c]pyrazol-5-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl-methyl}acetamide
• 英文别名: RWJ-416457；N-[[(5S)-3-[4-(2,6-dihydro-2-methylpyrrolo[3,4-c]pyrazol-5(4H)-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide；Acetamide, N-(((5S)-3-(4-(2,6-dihydro-2-methylpyrrolo(3,4-c)pyrazol-5(4H)-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl)methyl)-；N-[[(5S)-3-[3-fluoro-4-(2-methyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
• CAS: 474016-05-2
• 化学式: C₁₈H₂₀FN₅O₃
• 分子量: 373.387
• InChiKey: UCBHICFFJKDMMR-AWEZNQCLSA-N

物化性质

• 沸点：
  647.5±55.0 °C(Predicted)
• 密度：
  1.48±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  79.7
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N-{(5S)-3-[4-(5,6-dihydro-2H,4H-2-methylpyrrolo[3,4-c]pyrazol-5-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl-methyl}acetamide 在 sodium hexamethyldisilazane 、 caesium carbonate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.5h， 生成 4-(bis-benzyloxy-phosphoryloxymethyl)-benzoic acid (acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester
  参考文献：
  名称：

  ANTIMICROBIAL OXAZOLIDINONE PRODRUGS

  摘要：

  这项发明包括本文所定义的Formula (I)和Formula (II)的噁唑烷酮前药化合物。这些前药可以通过自然生物过程转化为一种具有抗微生物特性的活性成分，可用于治疗哺乳动物体内的细菌感染。

  公开号：

  US20080027053A1
• 作为产物：
  描述：

  草酸甲基肼 、 在 草酸甲基肼 作用下， 生成 N-{(5S)-3-[4-(5,6-dihydro-2H,4H-2-methylpyrrolo[3,4-c]pyrazol-5-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl-methyl}acetamide
  参考文献：
  名称：

  [EN] ANTIBACTERIAL HETEROBICYCLIC SUBSTITUTED PHENYL OXAZOLIDINONES
  [FR] PHENYL-OXAZOLIDINONES SUBSTITUTEES HETEROBICYCLIQUES ANTIBACTERIENNES

  摘要：

  公式（I）中的二环杂环取代苯并噁唑啉化合物：其中Y是公式（II）或（III）的基团，其中取代基在描述中具有所示的含义。这些化合物可用作抗菌剂。

  公开号：

  WO2001042242A1

文献信息

• Polymeric micromulsions
  申请人：Arien Maria Eduarda Albertina

  公开号：US20060034797A1

  公开（公告）日：2006-02-16

  The invention provides novel self-emulsifying diblock copolymers and novel self-emulsifying compositions comprising an active ingredient and a diblock copolymer characterized in that the diblock copolymer is liquid at a temperature below 50° C. and the composition is non-aqueous and liquid at a temperature below 50° C.

  本发明提供了新型自乳化二嵌段共聚物和由活性成分和二嵌段共聚物组成的新型自乳化组合物，其特征在于二嵌段共聚物在温度低于50℃时为液态，组合物在温度低于50℃时为非水性液态。
• A novel oxazolidinone antibiotic: RWJ-416457
  作者：Eugene Y. Cheung、Matthew L. Peterson、Renato Chiarella、Bruce M. Foxman

  DOI：10.1107/s0108270110009339

  日期：2010.5.15

  The crystal structure of the antibiotic drug candidate RWJ-416457 (systematic name: N-(5S)-3-[4-(5,6-dihydro-2H, 4H-2-methylpyrrolo[3,4-c]pyrazol-5-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl} acetamide), C18H20FN5O3, which belongs to the first new class of antibiotics discovered in the past 30 years, has been determined at 150 K. Each molecule of this drug donates one hydrogen bond to a neighboring molecule and accepts one hydrogen bond to give (O=C-R-N-H center dot center dot center dot O=C-R-N-H center dot center dot center dot)(n) linkages along the b-axis direction. The compound contains a pyrrolopyrazole ring, which, owing to its uncommon structure, has been shown to have particular effectiveness against multi-drug-resistant bacteria.
• POLYMERIC MICROEMULSIONS
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：EP1504047A1

  公开（公告）日：2005-02-09
• Liposomal delivery vehicle for hydrophobic drugs
  申请人：Zhang Yuanpeng

  公开号：US20070014845A1

  公开（公告）日：2007-01-18

  A liposome composition having a high drug concentration of a hydrophobic drug and capable of retaining the drug in entrapped form is described. The liposomes are comprised of high phase transition lipid and a lipopolymer, which together permit retention of a high concentration of a drug/cyclodextrin complex that achieves a high drug load that is retained even in the presence of a transmembrane osmotic gradient caused by the cyclodextrin.
• NOVEL CRYSTAL OF N-[[(5S)-3-[4-(2,6-DIHYDRO-2-METHYLPYRROLO[3,4-C]PYRAZOL-5(4H)-YL)-3-FLUOROPHENYL]-2-OXO-5-OXAZOLIDINYL]METHYL]ACETAMIDE
  申请人：Chiarella A. Renato

  公开号：US20080091026A1

  公开（公告）日：2008-04-17

  The present invention relates to a novel crystal of the Active Pharmaceutical Ingredient (API) N-[[(5S)-3 -[4-(2,6-dihydro-2-methylpyrrolo[3,4-c]pyrazol-5(4H)-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide, methods for the preparation of this crystal, pharmaceutical compositions comprising this crystal, and methods of treating a patient with this crystal.